HK1034913A1 - Pharmaceutical composition comprising a combination of metformin and fibrate, and its use for the preparation of medicines intended to reduce hyperglycaemia. - Google Patents

Pharmaceutical composition comprising a combination of metformin and fibrate, and its use for the preparation of medicines intended to reduce hyperglycaemia.

Info

Publication number
HK1034913A1
HK1034913A1 HK01105732A HK01105732A HK1034913A1 HK 1034913 A1 HK1034913 A1 HK 1034913A1 HK 01105732 A HK01105732 A HK 01105732A HK 01105732 A HK01105732 A HK 01105732A HK 1034913 A1 HK1034913 A1 HK 1034913A1
Authority
HK
Hong Kong
Prior art keywords
fibrate
metformin
preparation
combination
pharmaceutical composition
Prior art date
Application number
HK01105732A
Other languages
English (en)
Inventor
Yves Bonhomme
Philippe Briet
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of HK1034913A1 publication Critical patent/HK1034913A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HK01105732A 1998-02-12 2001-08-15 Pharmaceutical composition comprising a combination of metformin and fibrate, and its use for the preparation of medicines intended to reduce hyperglycaemia. HK1034913A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9801709A FR2774591B1 (fr) 1998-02-12 1998-02-12 Composition pharmaceutique comprenant l'association metformine et fibrate et son utilisation pour la preparation de medicaments destines a reduire l'hyperglycemie
PCT/EP1999/000614 WO1999040904A2 (en) 1998-02-12 1999-01-30 Pharmaceutical composition comprising a combination of metformin and fibrate, and its use for the treatment of hyperglycemia

Publications (1)

Publication Number Publication Date
HK1034913A1 true HK1034913A1 (en) 2001-11-09

Family

ID=9522912

Family Applications (1)

Application Number Title Priority Date Filing Date
HK01105732A HK1034913A1 (en) 1998-02-12 2001-08-15 Pharmaceutical composition comprising a combination of metformin and fibrate, and its use for the preparation of medicines intended to reduce hyperglycaemia.

Country Status (28)

Country Link
US (1) US6372790B1 (uk)
EP (1) EP1054665B1 (uk)
JP (1) JP4767411B2 (uk)
KR (1) KR100567608B1 (uk)
CN (1) CN1151785C (uk)
AR (1) AR018286A1 (uk)
AT (1) ATE204754T1 (uk)
AU (1) AU746821B2 (uk)
BR (1) BRPI9907866B8 (uk)
CA (1) CA2320039C (uk)
CZ (1) CZ290101B6 (uk)
DE (1) DE69900249T2 (uk)
DK (1) DK1054665T3 (uk)
ES (1) ES2162517T3 (uk)
FR (1) FR2774591B1 (uk)
HK (1) HK1034913A1 (uk)
HU (1) HU224619B1 (uk)
ID (1) ID26254A (uk)
MY (1) MY118164A (uk)
NO (1) NO328314B1 (uk)
PL (1) PL196874B1 (uk)
PT (1) PT1054665E (uk)
RU (1) RU2207850C2 (uk)
SK (1) SK283212B6 (uk)
TW (1) TW518222B (uk)
UA (1) UA70315C2 (uk)
WO (1) WO1999040904A2 (uk)
ZA (1) ZA991077B (uk)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2216335T3 (es) * 1997-12-08 2004-10-16 Bristol-Myers Squibb Company Nuevas sales de metformina y procedimiento.
US6982281B1 (en) 2000-11-17 2006-01-03 Lipocine Inc Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs
FR2796551B1 (fr) * 1999-07-23 2003-07-25 Lipha Nouveaux sels de metformine, leur procede d'obtention et les compositions pharmaceutiques en renfermant
FR2796940B1 (fr) * 1999-07-26 2005-04-08 Lipha Nouveaux sels de metformine, leur procede d'obtention et les compositions pharmaceutiques en renfermant
US6586438B2 (en) 1999-11-03 2003-07-01 Bristol-Myers Squibb Co. Antidiabetic formulation and method
US7151191B2 (en) * 2000-01-13 2006-12-19 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US6531158B1 (en) * 2000-08-09 2003-03-11 Impax Laboratories, Inc. Drug delivery system for enhanced bioavailability of hydrophobic active ingredients
JP4829411B2 (ja) * 2001-02-23 2011-12-07 キッセイ薬品工業株式会社 Ｃ型慢性肝炎治療剤
GB0119480D0 (en) 2001-08-09 2001-10-03 Jagotec Ag Novel compositions
WO2003105809A1 (en) 2002-06-17 2003-12-24 Themis Laboratories Private Limited Multilayer tablets containing thiazolidinedione and biguanides and methods for producing them
EP1424070A1 (en) * 2002-11-28 2004-06-02 Fournier Laboratories Ireland Limited Combination of a PPAR alpha agonist and metformin for decreasing the serum triglycerides
EP1569623B1 (en) 2002-12-13 2008-10-15 Jagotec Ag A topical nanoparticulate spironolactone formulation
FR2851734B1 (fr) * 2003-02-28 2006-06-09 Galenix Innovations Procede pour la fabrication d'une composition pharmaceutique sous la forme de comprimes contenant un fibrate et comprimes obtenus selon le procede
FR2858556B1 (fr) * 2003-08-06 2006-03-10 Galenix Innovations Composition pharmaceutique solide dispersible et/ou orodispersible non pelliculee contenant au moins le principe actif metformine, et procede de preparation
US8062664B2 (en) * 2003-11-12 2011-11-22 Abbott Laboratories Process for preparing formulations of lipid-regulating drugs
EP1696897B1 (en) 2003-12-19 2011-07-06 Omega Bio-Pharma (I.P.3) Limited Compositions for treating diabetes
EP1559419A1 (en) * 2004-01-23 2005-08-03 Fournier Laboratories Ireland Limited Pharmaceutical formulations comprising metformin and a fibrate, and processes for their obtention
WO2005074909A1 (ja) * 2004-02-09 2005-08-18 Aska Pharmaceutical Co., Ltd. 併用医薬
EP1591114A1 (en) * 2004-03-12 2005-11-02 Fournier Laboratories Ireland Limited Use of metformin and orlistat for the treatment or prevention of obesity
US20060286182A1 (en) * 2005-06-21 2006-12-21 Abeille Pharmaceuticals, Inc. Synergistic cinnamon combinations and methods for enhancing insulin activity
GB0602639D0 (en) * 2006-02-09 2006-03-22 Novartis Ag Organic compounds
CA2657394A1 (en) 2006-08-04 2008-02-07 Aska Pharmaceutical Co., Ltd. Preparation containing fibrate agent and process for producing the same
CN101342164B (zh) * 2007-08-21 2011-04-20 阜新市仙鹤制药有限责任公司 苯扎贝特控释制剂及其制备方法
US11304960B2 (en) 2009-01-08 2022-04-19 Chandrashekar Giliyar Steroidal compositions
US9339458B2 (en) * 2009-02-18 2016-05-17 Itf Research Pharma, S.L.U. Use of vaginal insulin sensitizing agents
ES2344183B1 (es) * 2009-02-18 2011-06-10 Italfarmaco, S.A. Uso de agentes sensibilizantes a insulina por via vaginal.
US9358241B2 (en) 2010-11-30 2016-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US20180153904A1 (en) 2010-11-30 2018-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US9034858B2 (en) 2010-11-30 2015-05-19 Lipocine Inc. High-strength testosterone undecanoate compositions
US20120148675A1 (en) 2010-12-10 2012-06-14 Basawaraj Chickmath Testosterone undecanoate compositions
JP2012171911A (ja) 2011-02-22 2012-09-10 Kao Corp Ｐｐａｒ活性化剤
US8765811B2 (en) * 2012-07-10 2014-07-01 Thetis Pharmaceuticals Llc Tri-salt form of metformin
US9382187B2 (en) * 2012-07-10 2016-07-05 Thetis Pharmaceuticals Llc Tri-salt form of metformin
BR112015000368A2 (pt) * 2012-07-10 2017-06-27 Thetis Pharmaceuticals Llc forma de tri-sais de metformina
US9505709B2 (en) 2014-05-05 2016-11-29 Thetis Pharmaceuticals Llc Compositions and methods relating to ionic salts of peptides
US10166246B2 (en) 2014-05-27 2019-01-01 City Of Hope TGR5 agonist complexes for treating diabetes and cancer
EP3157936B1 (en) 2014-06-18 2018-10-17 Thetis Pharmaceuticals LLC Mineral amino-acid complexes of active agents
US9242008B2 (en) 2014-06-18 2016-01-26 Thetis Pharmaceuticals Llc Mineral amino-acid complexes of fatty acids
WO2016033549A2 (en) 2014-08-28 2016-03-03 Lipocine Inc. (17-ß)-3-OXOANDROST-4-EN-17-YL TRIDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE
WO2016033556A1 (en) 2014-08-28 2016-03-03 Lipocine Inc. BIOAVAILABLE SOLID STATE (17-β)-HYDROXY-4-ANDROSTEN-3-ONE ESTERS
FR3050112B1 (fr) * 2016-04-15 2020-09-04 Soc Civ Immobiliere Gecinq Utilisation de l'acide fenofibrique dans le traitement des maladies hepatiques
CA3026264A1 (en) 2016-06-03 2017-12-07 Thetis Pharmaceuticals Llc Compositions and methods relating to salts of specialized pro-resolving mediators
US10344002B2 (en) 2016-09-26 2019-07-09 Nusirt Sciences, Inc. Compositions and methods for treating metabolic disorders
FR3056908B1 (fr) * 2016-09-30 2019-04-19 Nashpharm Sel de metformine et d'elafibranor presentant une activite duale pour le traitement de l'obesite associee a la steato-hepatite non alcoolique (nash) et a l'hypertriglyceridemie
US20180147215A1 (en) 2016-11-28 2018-05-31 Lipocine Inc. Oral testosterone undecanoate therapy
GB2599950A (en) * 2020-10-16 2022-04-20 Zentiva Ks Pharmaceutical compositions with low amounts of nitrosamine impurities and methods for producing the same
WO2023119100A1 (en) * 2021-12-22 2023-06-29 Mankind Pharma Ltd. Stable pharmaceutical compositions

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2264525B1 (uk) * 1974-03-22 1977-11-04 Expl Marques Brevets Et
US4080472A (en) 1974-03-22 1978-03-21 Societe D'etudes Et D'exploitation De Marques Et Brevets S.E.M.S. Metformin 2-(p-chlorophenoxy)-2-methylpropionate
DE3729209A1 (de) 1987-09-01 1989-03-09 Boehringer Mannheim Gmbh Verwendung von bezafibrat zur behandlung von diabetes
JP3852621B2 (ja) * 1992-01-21 2006-12-06 あすか製薬株式会社 血管内皮細胞機能改善剤
WO1998005331A2 (en) * 1996-08-02 1998-02-12 Ligand Pharmaceuticals Incorporated Prevention or treatment of type 2 diabetes or cardiovascular disease with ppar modulators

Also Published As

Publication number Publication date
TW518222B (en) 2003-01-21
KR20010040925A (ko) 2001-05-15
ID26254A (id) 2000-12-07
AR018286A1 (es) 2001-11-14
US6372790B1 (en) 2002-04-16
SK11562000A3 (sk) 2000-12-11
DE69900249D1 (de) 2001-10-04
PL196874B1 (pl) 2008-02-29
NO328314B1 (no) 2010-01-25
UA70315C2 (en) 2004-10-15
NO20004056D0 (no) 2000-08-11
SK283212B6 (sk) 2003-03-04
HUP0100801A2 (hu) 2001-08-28
BRPI9907866B1 (pt) 2017-08-15
FR2774591B1 (fr) 2000-05-05
CA2320039A1 (en) 1999-08-19
CZ290101B6 (cs) 2002-05-15
ZA991077B (en) 1999-08-11
RU2207850C2 (ru) 2003-07-10
WO1999040904A2 (en) 1999-08-19
DE69900249T2 (de) 2002-06-13
FR2774591A1 (fr) 1999-08-13
ATE204754T1 (de) 2001-09-15
MY118164A (en) 2004-09-30
HUP0100801A3 (en) 2001-12-28
CA2320039C (en) 2008-07-22
EP1054665A2 (en) 2000-11-29
EP1054665B1 (en) 2001-08-29
BRPI9907866B8 (pt) 2021-05-25
AU2923399A (en) 1999-08-30
AU746821B2 (en) 2002-05-02
ES2162517T3 (es) 2001-12-16
DK1054665T3 (da) 2001-12-27
HU224619B1 (hu) 2005-11-28
CN1290160A (zh) 2001-04-04
PT1054665E (pt) 2002-02-28
PL342665A1 (en) 2001-07-02
CN1151785C (zh) 2004-06-02
KR100567608B1 (ko) 2006-04-04
WO1999040904A3 (en) 1999-09-30
NO20004056L (no) 2000-08-11
JP2002502869A (ja) 2002-01-29
BR9907866A (pt) 2000-10-31
CZ20002828A3 (cs) 2000-11-15
JP4767411B2 (ja) 2011-09-07

Similar Documents

Publication Publication Date Title
ZA991077B (en) Pharmaceutical composition comprising a combination of metformin and fibrate, and its use for the preparation of medicines intended to reduce hyperglycaemia.
ZA200203368B (en) Pharmaceutical composition comprising a combination of metformin and glibenclamide.
HUP0400932A3 (en) Pharmaceutical composition containing nateglinide and another antidiabetic compound, process for its preparation and for use the same
HUP0104497A3 (en) Benzamide derivatives, their preparation, medicaments containing them and their use
HUP0200714A3 (en) Pharmaceutical compounds, pharmaceutical compositions containing them and their use
HUP0004040A3 (en) Pleuromutilin derivatives as antimicrobials, process for their preparation, pharmaceutical compositions, comprising thereof and their use
HUP0100101A3 (en) Prostaglandin agonists, pharmaceutical compositions comprising thereof and their use
ZA979220B (en) New oxadiazoles, processes for their preparation and their use as pharmaceutical compositions.
HUP0104579A3 (en) Glp-1 analogues, pharmaceutical compositions comprising thereof and their use
ZA200107983B (en) New compounds, their preparation and use.
ZA973022B (en) New pharmaceutical composition with anaesthetic effect.
ZA200202521B (en) 2'-substituted 1,1'-biphenyl-2-carbonamides, method for the production thereof, use thereof as a medicament and pharmaceutical preprations containing said compounds.
HUP0103884A3 (en) Arylsulfonanilide urea-derivatives, pharmaceutical compositions containing them and their use
IL149139A0 (en) Pharmaceutical compositions containing metformin and glyburide
IL140897A0 (en) Benzocycloheptene derivatives, processes for the preparation thereof and pharmaceutical compositions containing the same
PL343512A1 (en) Thienylazolylalcoxyethanamines, their preparation and their application as medicaments
IL150383A0 (en) Glyburide and pharmaceutical compositions containing the same
HUP0102255A3 (en) Vla-4 inhibitor omepupa-v, pharmaceutical compositions comprising thereof and their use
CZ2006533A3 (cs) Amorfní ritonavir, způsoby jeho přípravy, jeho použití a farmaceutická kompozice ho obsahující
HRP950363A2 (en) Novel chemical compound, its preparation and use as a drug
HUP9902166A3 (en) Substituted benzamide derivatives having anticonvulsant activity, preparation and use thereof, pharmaceutical compositions containing these compounds
HK1035719A1 (en) Azabicyclic compounds, pharmaceutical composition containing them and their medicinal use
HUP0200121A3 (en) Calcilytic compounds, pharmaceutical compositions containing them and their use
HUP0001940A3 (en) Benzisothiazole derivatives, their use and pharmaceutical compositions containing them
EP0641207A4 (en) ENANTIOMERIC CYNEMICIN ANALOGS, THEIR PREPARATION AND USE.

Legal Events

Date Code Title Description
PE Patent expired

Effective date: 20190129